Package Leaflet: Information for the User
Efmody 5 mg modified-release hard capsules
Efmody 10 mg modified-release hard capsules
Efmody 20 mg modified-release hard capsules
hydrocortisone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Efmody contains the active substance hydrocortisone. Hydrocortisone belongs to a group of medicines called corticosteroids.
Hydrocortisone is a copy of the hormone cortisol. Cortisol is produced in the body by the adrenal glands. Efmody is used when the adrenal glands do not produce enough cortisol due to a hereditary disorder called congenital adrenal hyperplasia. It is indicated in adults and adolescents from 12 years of age.
Do not take Efmody
Warnings and precautions
Tell your doctor or pharmacist before you start taking Efmody if you have any of the following conditions:
Acute adrenal insufficiency
Infections
Vaccination
Others
Do not stop taking Efmody without consulting your doctor, as you may become very ill quickly.
As Efmody replaces the normal hormone that your body lacks, side effects are less likely; however:
Other medicines and Efmody
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Some medicines affect how Efmody works, which may mean that your doctor needs to change the dose of Efmody.
Your doctor may need to increase the dose of Efmody if you are taking certain medicines, including:
Your doctor may need to decrease the dose of Efmody if you are taking certain medicines, including:
Taking Efmody with food and drink
Some foods and drinks affect how Efmody works, and your doctor may need to decrease the dose. These include:
Pregnancy, breastfeeding, and fertility
Hydrocortisone is known to cross the placenta during pregnancy and is present in breast milk, but it has not been shown to cause harm to the breastfed child. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
Efmody has a minor influence on the ability to drive and use machines. Untreated adrenal insufficiency may affect the ability to drive and use machines. Tell your doctor immediately if you feel tired or dizzy after taking Efmody.
Always take this medicine exactly as your doctor, nurse, or pharmacist has told you. If you are not sure, check with your doctor.
Your doctor will decide the correct initial dose of Efmody and then adjust the dose according to your needs. During illness, before and after surgery, and in situations of intense stress, your doctor may ask you to take another corticosteroid instead of or in addition to Efmody.
The initial daily dose may be divided into two doses, with two-thirds to three-quarters of the daily dose taken at bedtime and the rest in the morning.
The morning dose of hydrocortisone in modified-release hard capsules should be taken on an empty stomach, at least 1 hour before food, and the evening dose should be taken at least 2 hours after the last meal of the day.
Use in children
There is no information on the safety and efficacy of Efmody in children under 12 years of age. Other hydrocortisone medicines are available for children under 12 years of age.
How to take this medicine
Swallow the capsules with water.
Do not chew them, as this may alter the release of the medicine.
If you take more Efmody than you should
If you have taken more Efmody than you should, contact your doctor or pharmacist as soon as possible for advice on what to do.
If you forget to take Efmody
If you miss a dose, take it as soon as possible.
If you stop taking Efmody
Do not stop taking Efmody without consulting your doctor first. Stopping the medicine suddenly may cause acute adrenal insufficiency.
If you become ill
Tell your doctor or pharmacist if you become ill, are under stress, are injured, or are going to have an operation, as your doctor may advise you to take another corticosteroid instead of or in addition to Efmody (see section 2).
If you take too much Efmody
Rarely, overdose or death associated with excessive Efmody may occur, but you should tell your doctor immediately.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor as soon as possible if you experience any of the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Long-term treatment with hydrocortisone may reduce bone density. Your doctor will monitor the condition of your bones (see section 2).
People who need steroid treatment may have a higher risk of heart disease. Your doctor will monitor you for this.
Long-term treatment with hydrocortisone may affect growth in children and adolescents. Your doctor will monitor the growth of young patients. Some children with congenital adrenal hyperplasia treated with hydrocortisone may have puberty earlier than expected. Your doctor will monitor the sexual development of these patients (see section 2).
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.
The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Store in the original package.
Keep the bottle tightly closed to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Efmody contains
? Efmody 5 mg modified-release hard capsules: each modified-release capsule contains 5 mg of hydrocortisone
? Efmody 10 mg modified-release hard capsules: each modified-release capsule contains 10 mg of hydrocortisone
? Efmody 20 mg modified-release hard capsules: each modified-release capsule contains 20 mg of hydrocortisone
Capsule
The capsule is made of gelatin.
Efmody 5 mg modified-release hard capsules (white/blue)
Titanium dioxide (E171) and indigo carmine (E132)
Efmody 10 mg modified-release hard capsules (white/green)
Titanium dioxide (E171), indigo carmine (E132), and yellow iron oxide (E172)
Efmody 20 mg modified-release hard capsules (white/orange)
Titanium dioxide (E171), yellow iron oxide (E172), and red iron oxide (E172)
Printing ink
The printing ink of the capsules contains shellac, black iron oxide (E172), propylene glycol, and potassium hydroxide.
Appearance and packaging
Capsule (approx. 19 mm in length) with blue opaque cap and white opaque body with the imprint «CHC 5 mg» containing a white or almost white granulate.
Capsule (approx. 19 mm in length) with green opaque cap and white opaque body with the imprint «CHC 10 mg» containing a white or almost white granulate.
Capsule (approx. 22 mm in length) with orange opaque cap and white opaque body with the imprint «CHC 20 mg» containing a white or almost white granulate.
Efmody is available in high-density polyethylene bottles with a child-resistant polypropylene screw cap and integrated desiccant. Each bottle contains 50 modified-release hard capsules.
Pack size:
Bottle with 1 bottle of 50 modified-release hard capsules.
Bottle with 2 bottles of 50 modified-release hard capsules (100 capsules).
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Diurnal Europe B.V.
Van Heuven Goedhartlaan 935 A
1181LD Amstelveen
Netherlands
Manufacturer
Delpharm Lille SAS
Parc d'Activités Roubaix-Est
22 rue de Toufflers CS 50070
Lys Lez Lannoy, 59 452
France
Wasdell Europe Limited
IDA Dundalk Science and Technology Park
Mullagharlin
Dundalk
Co. Louth, A91 DET0
Ireland
Date of last revision of this leaflet
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.